HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Journal of Clinical Investigation · 01.04.2024 · 134 (7)
DOI: 10.1172/jci176454 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.02.2024. Verfasst von Zheqi Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR). METHODS To investigate cellular and molecular differences among tumors according to HER2 heterogeneity and pCR, we performed RNA sequencing and ERBB2 FISH of 285 pretreatment and posttreatment tumors from 129 patients in this T-DM1+P neoadjuvant trial. A subset of cases was also subject to NanoString spatial digital profiling. RESULTS Pretreatment tumors from patients with pCR had the highest level of ERBB2 mRNA and ERBB signaling. HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K pathway enrichment and luminal features. HET tumors showed minimal treatment-induced transcriptomic changes compared with non-HET tumors. Immune infiltration correlated with pCR and HER2-HET status. CONCLUSION Resistance mechanisms in HET and non-HET tumors are distinct. HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors. TRIAL REGISTRATION ClinicalTrials.gov NCT02326974. FUNDING This study was funded by Roche and the National Cancer Institute.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
- University of Milan, School of Medicine, Milan, Italy.
- Harvard University, Cambridge, Massachusetts, USA.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Li, Z., Metzger Filho, O., Viale, G., dell'Orto, P., Russo, L., Goyette, M. A., Kamat, A., Yardley, D. A., Gupta Abramson, V., Arteaga, C. L., Spring, L. M., Chiotti, K., Halsey, C., Waks, A. G., King, T. A., Lester, S. C., Bellon, J. R., Winer, E. P., Spellman, P. T., …, & Polyak, K. (2024). HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. Journal of Clinical Investigation, 134(7). https://doi.org/10.1172/jci176454
Vancouver
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, et al. HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. Journal of Clinical Investigation. 2024;134(7). doi:10.1172/jci176454
BibTeX
@article{Li2024,
author = {Li, Zheqi and Metzger Filho, Otto and Viale, Giuseppe and dell'Orto, Patrizia and Russo, Leila and Goyette, Marie-Anne and Kamat, Avni and Yardley, Denise A and Gupta Abramson, Vandana and Arteaga, Carlos L and Spring, Laura M and Chiotti, Kami and Halsey, Carol and Waks, Adrienne G and King, Tari A and Lester, Susan C and Bellon, Jennifer R and Winer, Eric P and Spellman, Paul T and Krop, Ian E and Polyak, Kornelia},
title = {HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {7},
doi = {10.1172/jci176454}
}
EUVIMED